Company Description

LB Pharmaceuticals is a clinical-stage biopharmaceutical company developing novel therapies for the treatment of schizophrenia, bipolar depression, and other neuropsychiatric diseases. They are building a pipeline that leverages the broad therapeutic potential of their lead product candidate, LB-102, which they believe has the potential to be the first benzamide antipsychotic drug approved for neuropsychiatric disorders in the United States.